Cerenome Q3 2026: CNSide Revenue Hits $0.7M, Cash Falls to $4.9M

Cerenome, Inc. (Nasdaq: CNSY) reported on 13 November 2026 its first quarter of CNSide diagnostic revenue, booking $0.7 million net against $1.55 million in gross billings at list prices, alongside a net loss of $8.7 million, or $1.14 per share. Cash, cash equivalents and investments fell to $4.9 million on 30 September from $8.6 million on 30 June. The Houston-based CNS oncology company, which rebranded from Plus Therapeutics and began trading under the CNSY symbol on 3 August, filed the results as Exhibit 99.1.

Context — why Cerenome's first diagnostic revenue quarter matters now

The quarter marks the first time Cerenome has reported revenue from selling a product rather than from grant funding. A year earlier, total revenue of $1.4 million was entirely grant revenue, with no diagnostic line at all. The shift changes what the income statement measures: grant revenue reflects research progress, while diagnostic revenue reflects whether cancer centers actually order and pay for the test.

The company said about 80% of U.S. private payers now sit under contract, representing roughly 190 million covered lives. That footprint expanded through agreements with Medical Mutual, Health Care Service Corporation and Blue Cross Blue Shield of Michigan, plus in-network deals with Florida Blue and Aetna. The Aetna agreement, effective 1 November, is the company's first national CNSide payer contract covering both tumor cell enumeration and molecular profiling.

Management framed the revenue line as a landmark. Chief Executive Marc H. Hedrick said recognition of the first quarter of CNSide diagnostic revenue and commercial payments beginning in October is a "tremendous landmark," and pointed to the growing payer universe as giving physicians an in-network option.

What triggered the reporting event is the standard quarterly cycle, but the catalyst chain behind it is commercial rather than clinical. Cerenome launched CNSide CSF Molecular Profile tests for solid tumors and hematologic malignancies, available to order from 12 October, and selected XiFin for revenue cycle management and clearinghouse services. Both steps are prerequisites for converting orders into collected cash rather than billed claims.

The report gives no prior-year diagnostic comparable, so the only clean comparison is sequential: zero diagnostic revenue in the third quarter of 2025 against $0.7 million now. Medicare reimbursement is targeted for the first half of 2027, with a separate coverage determination being pursued from Novitas Solutions.

Data — what the numbers show

The revenue line is small relative to the cost base. Cost of revenue was $0.9 million against $0.7 million of diagnostic revenue, so the diagnostic segment ran at a gross loss in its first quarter. Research and development expense was $2.1 million, down from $2.4 million a year earlier. Selling, general and administrative expense was $5.2 million, up from $3.4 million, reflecting the build-out of the commercial team.

Operating loss widened to $7.5 million from $4.5 million. Net loss widened to $8.7 million, or $1.14 per share, from $4.4 million, or $1.03 per share. The per-share loss grew more slowly than the dollar loss because the share count rose: 7,890,305 common shares were issued as of 30 September versus 5,557,371 at 31 December 2025.

Metric	Q3 2026	Q3 2025
Total revenue	$0.7M	$1.4M
Diagnostic revenue, net	$0.7M	$0.0M
Cost of revenue	$0.9M	$0.0M
R&D expense	$2.1M	$2.4M
SG&A expense	$5.2M	$3.4M
Operating loss	$7.5M	$4.5M
Net loss	$8.7M	$4.4M

Other income and expense swung to a net $1.2 million charge, driven by $1.6 million of financing expenses, partly offset by a $0.5 million favorable change in the fair value of financial instruments and $0.1 million of interest income. Total assets were $12.2 million against $16.3 million at year-end 2025, and total liabilities of $13.1 million exceed total assets, leaving stockholders' equity at a deficit of $0.9 million.

Analysis — what it means for CNSY holders and CNS oncology peers

The balance sheet is the central tension. Cerenome ended the quarter with $4.9 million in cash and investments against an operating loss that ran at $7.5 million in a single quarter. That arithmetic means the company depends on external funding to continue operating, and it has already acted: in September it closed a senior secured facility of up to $20 million with royalty-based repayments, and after quarter-end it raised $3.8 million under an Equity Distribution Agreement.

The royalty-based structure matters for how investors should read future revenue. If repayment is tied to royalties, a portion of CNSide collections may be directed to the lender rather than retained, which would make reported diagnostic revenue an imperfect proxy for cash available to fund the therapeutic pipeline. The report does not disclose the royalty rate or the repayment schedule, so the size of that claim on future collections cannot be quantified from the filing.

Second-order exposure runs to the diagnostic reimbursement chain rather than to large-cap pharma. Cerenome's economics depend on private payer contracts converting into paid claims and on a Medicare pathway arriving in the first half of 2027. Companies exposed to the same reimbursement mechanics include other laboratory-developed test developers seeking coverage decisions, though the report names no peers and gives no sector-level figures.

The counter-argument is that the revenue line is early. A first quarter of billings rarely reflects steady-state collection, and the company attributed the gap between $1.55 million gross and $0.7 million net to estimated payer adjustments and price concessions. If those adjustments narrow as the revenue cycle matures under XiFin, net revenue could rise without a matching increase in orders.

The offsetting risk is dilution. Share count rose by roughly 2.3 million shares over nine months, and the post-quarter equity raise adds further supply. Positioning reflects that split: holders are underwriting a reimbursement inflection, while the funding structure means existing shareholders absorb continued issuance.

Outlook — what to watch next

Cerenome hosts a conference call and webcast on Monday, 16 November 2026 at 8:30 a.m. Eastern Time to discuss the quarter. Beyond that, the report names three dated checkpoints: topline data from the Phase 2 ReSPECT-GBM study in recurrent glioblastoma expected in mid-2027, an End-of-Phase 2 meeting with the FDA thereafter, and Medicare reimbursement targeted for the first half of 2027.

On the diagnostics side, the company said it will expand CNSide adoption across cancer centers, build out the field sales team and enhance the testing menu. It also expects to continue dose escalation in the REYOBIQ leptomeningeal metastases multi-dose study. Enrollment in ReSPECT-GBM completed in October; the first ten patients in the multi-dose ReSPECT-LM cohort have been treated with no dose-limiting toxicities reported.

The report provides no price levels, moving averages or valuation multiples for CNSY, so there are no technical thresholds to cite. The observable variables are cash balance, diagnostic revenue net of payer adjustments, and whether the Novitas coverage determination or the Medicare pathway lands on schedule.

Frequently Asked Questions

What does Cerenome's first CNSide revenue quarter mean for retail investors?

It means the company has moved from grant-funded research to selling a product, but the diagnostic line ran at a gross loss in its debut quarter: $0.7 million of net diagnostic revenue against $0.9 million of cost of revenue. Combined with a $7.5 million quarterly operating loss, the business still consumes more cash than it generates, so funding risk remains the dominant consideration for anyone holding the stock.